Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics, Inc. (SWTX) is a clinical-stage biopharmaceutical company pioneering targeted therapies for rare diseases and oncology. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, regulatory milestones, and strategic collaborations.
Access authoritative information on SWTX's precision medicine pipeline, including FDA communications, clinical trial developments, and partnership announcements. Our curated collection features:
• Regulatory updates on approved therapies and review timelines
• Clinical trial progress across rare disease and oncology programs
• Research collaborations with academic institutions and industry leaders
• Scientific presentations at major medical symposiums
Bookmark this page for real-time access to verified SWTX developments. For comprehensive analysis of the company's therapeutic pipeline and market position, visit regularly for the latest updates directly from primary sources.
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: SWTX), will have its CEO, Saqib Islam, participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 12, 2021, at 3:00 p.m. EST. The live webcast can be accessed on their Investors & Media section. SpringWorks focuses on developing precision medicine for patients with rare diseases and cancer, advancing clinical trials for targeted oncology products. For more details, visit their website.
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced that CEO Saqib Islam will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 7:30 a.m. EST. The presentation will focus on the company’s commitment to developing life-changing medicines for patients with rare diseases and cancer. Investors can access the live webcast on the company’s website, with a replay available afterward. SpringWorks is at the forefront of clinical development, advancing targeted oncology products and strategic partnerships in the biopharmaceutical industry.
SpringWorks Therapeutics (Nasdaq: SWTX) has announced the promotions of Badreddin Edris to Chief Operating Officer and L. Mary Smith to Chief Development Officer. Edris has been pivotal in advancing the company's strategy for nirogacestat and has extensive background in biotechnology. Smith, a founding member, has successfully led clinical programs and regulatory strategies. CEO Saqib Islam praised their leadership, highlighting the importance of their roles in advancing clinical development programs for rare diseases and cancer.
SpringWorks Therapeutics (Nasdaq: SWTX) announced that CEO Saqib Islam will participate in a Fireside Chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 2, 2020, at 12:35 p.m. ET. The conference will be held virtually, and a video webcast can be accessed on the company's website under the 'Events & Presentations' section. A replay of the session will also be available for a limited time after the event.
SpringWorks focuses on precision medicine for rare diseases and cancer, advancing clinical trials for targeted oncology products.
SpringWorks Therapeutics has completed enrollment in its Phase 3 DeFi trial for nirogacestat targeting desmoid tumors. The company has signed clinical collaborations with major pharma players like Janssen, Pfizer, and Precision Biosciences to explore nirogacestat's potential in multiple myeloma therapies. Additionally, SpringWorks completed an agreement with Jazz Pharmaceuticals, receiving $35 million upfront and potential milestone payments up to $375 million. They raised $269.5 million through a follow-on public offering. R&D expenses increased to $13.9 million in Q3 2020, leading to a net loss of $21.7 million.
SpringWorks Therapeutics (Nasdaq: SWTX) has successfully completed its underwritten public offering, raising approximately $287.5 million through the sale of 5,637,254 shares at a price of $51.00 each. This total includes the full exercise of an underwriter's option for an additional 735,294 shares. J.P. Morgan, Goldman Sachs, and Cowen acted as joint book-running managers for this offering. The funds raised will support the company's clinical development of treatments for rare diseases and cancers.
SpringWorks Therapeutics (Nasdaq: SWTX) announced a public offering of 4,901,960 shares of common stock at $51.00 per share, aiming to raise approximately $250 million before expenses. The offering's close is expected around October 13, 2020, subject to customary conditions. Additionally, the underwriters hold a 30-day option to acquire up to 735,294 additional shares. J.P. Morgan, Goldman Sachs, and Cowen are the joint book-running managers for this offering. The registration statement has been filed with the SEC and is effective.
SpringWorks Therapeutics (Nasdaq: SWTX) has announced a proposed underwritten public offering of $150 million of its common stock, with an additional $22.5 million option for underwriters. All shares will be sold by the company, with the offering subject to market conditions. J.P. Morgan, Goldman Sachs, and Cowen act as joint managers for the offering. This follows an automatic shelf registration statement filed with the SEC. The funds from this offering are expected to enhance their development of targeted oncology products and support ongoing clinical trials.
SpringWorks Therapeutics has announced a collaboration with Pfizer to evaluate the investigational gamma secretase inhibitor, nirogacestat, in combination with Pfizer's anti-B-cell maturation antigen bispecific antibody, PF‐06863135, aimed at treating relapsed or refractory multiple myeloma. This collaboration marks the fifth partnership focused on nirogacestat as a BCMA potentiator. Pfizer will conduct a Phase 1b/2 study to assess the safety and efficacy of this combination therapy, with the study set to begin in the first half of 2021. Nirogacestat is also in Phase 3 development for desmoid tumors.
SpringWorks Therapeutics (Nasdaq: SWTX) has announced that CEO Saqib Islam will participate in a Fireside Chat at the H.C. Wainwright Precision Oncology Conference on September 24, 2020, at 9:30 a.m. EST. A video webcast will be available on the company’s website, with a replay accessible for 30 days post-event. SpringWorks focuses on developing therapies for rare diseases and cancer, advancing two late-stage clinical trials and building partnerships to enhance its portfolio.
